Market research
AMPE Ampio Pharmaceuticals, Inc
PINK USD Healthcare
Latest close
As of 05 Jun 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 208K
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 17.05
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 208K
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 17.05
About
About Ampio Pharmaceuticals, Inc
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Research context
Ampio Pharmaceuticals, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AMPE discussion.
5 years, 6 months ago
Ampio Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Ampio Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 352.7% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 39.2% to $-3M since the same quarter in the previous year.
Based on the above factors, Ampio Pharmaceuticals, Inc gets an overall score of 3/5.